An investigational oral therapy from PTC Therapeutics called PTC518 safely and effectively reduces levels of the mutant huntingtin protein (mHTT) in Huntington’s disease patients, while being linked to trends of slower disease progression. That’s according to one-year interim data from the ongoing Phase 2a PIVOT-HD clinical trial…
News
Significant impairments in cognitive function are evident in people with Huntington’s disease relative to healthy adults, as assessed with a disease-specific battery of cognitive tests, top-line data from a Phase 2 clinical trial show, meeting its main goal. The two-part trial, called SURVEYOR (NCT05358821), also evaluated the safety…
The effects of Ingrezza (valbenazine) on Huntington’s disease-associated chorea grew increasingly stronger over the course of the three-month Phase 3 KINECT-HD clinical trial, according to a post-hoc analysis. A post-hoc analysis is one planned and conducted after the trial has been completed. “This post-hoc analysis of the…
Clinical trials testing either tominersen, an experimental therapy designed to target the underlying cause of Huntington’s disease, or dalzanemdor, an oral candidate that aims to improve cognitive abilities, are currently enrolling Huntington’s patients in the U.S. Updates on the therapies’ clinical programs were provided by representatives of their…
The Huntington’s disease community was encouraged to step up and get involved in observational studies to help scientists better understand the neurodegenerative disorder and accelerate the development of potential treatments. Participating in research “is the greatest thing that we can do to help expedite treatments for HD [Huntington’s disease],”…
Establishing exercise routines and getting support from care partners can help people with Huntington’s disease stay active and maintain their mobility and function. In the past decade, new research on the effects of exercise has shown conclusively that aerobic exercise can help patients improve their fitness and motor…
Psychotherapy — talk therapy with a professional to help a person manage their emotional state and mental health — can be of benefit to people with Huntington’s disease, though finding the right therapist can require some “shopping around.” That’s according to Spencer Diehl, a licensed clinical social worker/therapist at…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to AMT-130, an experimental gene therapy for Huntington’s disease, the first time a Huntington’s treatment candidate has received such a designation. The RMAT designation is given to therapies that seek to treat, modify,…
For people with Huntington’s disease who are struggling to get a good night’s sleep, establishing good sleep hygiene — setting habits such as a regular bedtime routine and maintaining a cozy, dark sleeping space — may help. Other potential ways to improve sleep include treating those Huntington’s symptoms…
There’s a sore need to provide more psychological support to people living with Huntington’s disease and their families, not only around the time of testing and potential diagnosis, but throughout the different stages of the disease, according to a study released at the 2024 Huntington’s Disease Society…
Recent Posts
- Huntington’s treatment safely slows disease over 9 months in early trial
- A new puppy gives my gene-positive wife a sense of purpose
- Toward a better understanding of anger as a symptom of Huntington’s disease
- Actor Will Forte shares family story in Teva awareness campaign
- Finding ‘space in the middle’ to deal with life’s challenges
- What a compassionate reset looks like in life with Huntington’s
- Ingrezza engages with therapeutic target more strongly than Austedo
- Anticipation of a possible new clinical trial has us holding on to hope
- What caregiver burnout is really about — and what you can do about it
- Oral Huntington’s treatment aims to slow disease progression